The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape - European Medical Journal
×

Browse

The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape

| Download as | PDF
Chairpeople:
Manfred Wirth1
Speakers:
Fred Saad,2 Joe O’Sullivan,3 Anders Bjartell,4 Wolfgang Loidl5
Disclosure:

Speakers participating in this symposium received honorarium from Bayer Healthcare.

Acknowledgements:

Writing assistance provided by Dr Tabasum Mughal.

Support:

The publication of this article was funded by Bayer Healthcare. The views and opinions expressed are those of the authors and not necessarily of Bayer Healthcare.

Citation
EMJ Urol. ;1[1]:28-32.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The Bayer-sponsored satellite symposium brought together a range of experts in the field of metastatic castrate-resistant prostate cancer (mCRPC), including Professors Fred Saad, Joe O’Sullivan, Anders Bjartell, Wolfgang Loidl, and Manfred Wirth. This distinguished faculty came together to discuss the changing paradigm and therapeutic options available in the management of mCRPC, offering the opportunity for interactive audience participation to discuss the current treatment landscape.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.